This discovery could influence treatment strategies for chronic myeloid leukemia (CML) and related cancers. The study, ...

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...

Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent among East Asians that ...

Of these, chronic myeloid leukemia (CML) is a subtype that primarily affects the bone marrow, which produces blood cells. The Duke-NUS scientists, in collaboration with their partners, including ...

Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

More than 95% of chronic myeloid leukemia (CML) and 20%-30% of acute lymphoblastic leukemia (ALL) patients express the fusion ...

Every year, approximately 700 Canadians are diagnosed with chronic myeloid leukemia (CML), a type of blood cancer that starts in the bone marrow. While there is no cure, people with CML today have a ...

A new approach helps examine the proportion of cancerous and healthy stem cells in patients with chronic myeloid leukemia and how this influences treatment outcomes.

Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.

The global leukemia therapeutics treatment market has seen considerable growth, progressing from USD 14,504.8 million in 2022 to USD 15,246.7 million in 2023. With a projected compound annual growth ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...